Jean François Berdah

Hôpital Sainte-Marguerite — France

Medicine · Health Sciences

12h-index1.5kcitations54works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(18), Cancer Treatment and Pharmacology(14), Prostate Cancer Diagnosis and Treatment(9), Radiopharmaceutical Chemistry and Applications(7), Breast Cancer Treatment Studies(5)

Publications52 total

Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
Journal of Clinical Oncology·2023· 54 cited
Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.
Journal of Clinical Oncology·2023· 19 cited
1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial
Annals of Oncology·2022· 12 cited
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma
Cells·2021· 12 citedOpen Access
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
European Urology·2021· 39 cited
LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
Annals of Oncology·2021· 52 cited
A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with <i>de novo</i> metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
Journal of Clinical Oncology·2021· 40 cited
Rechallenge of nivolumab in metastatic renal cell carcinoma, an ambispective multicenter study (RENIVO).
Journal of Clinical Oncology·2021· 2 cited
Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2019· 2 cited
ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2018· 2 cited
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial
European Urology·2017· 63 cited
A Cost-Utility Analysis Comparing Two Sequences of Treatment for First-Line Chemotherapy in Metastatic Prostate Cancer (MCRPC): Cabazitaxel Followed by Docetaxel Versus Docetaxel Followed by Cabazitaxel
Value in Health·2017· 1 cited
Management of metastatic prostate cancer patients in first line: Audit of real-life practices.
Journal of Clinical Oncology·2016
433 Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma (mRCC)
European Journal of Cancer·2015· 3 cited
Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.
Journal of Clinical Oncology·2014· 11 cited
A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in high-risk localized prostate cancer (GETUG 12).
Journal of Clinical Oncology·2014· 4 cited
Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)
European Journal of Cancer·2014· 65 cited
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)
European Journal of Cancer·2013· 12 citedOpen Access
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
The Lancet Oncology·2013· 727 cited
Cisplatin-Docetaxel Induction plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients: A Phase II Trial
Oncology·2012· 10 cited
page 1 of 3Next →

Frequent Co-authors

Karim Fizazi(14), Gwénaëlle Gravis(13), R. Delva(9), Aude Fléchon(9), Stéphane Oudard(8), Christine Théodore(8), Florence Joly(7), Loı̈c Mourey(7), Ali Hasbini(7), Franck Priou(6), I. Krakowski(6), Muriel Habibian(6), Marjorie Baciuchka(6), Frédéric Rolland(5), Philippe Beuzeboc(5), Stéphanie Foulon(5), Stéphane Culine(5), Ray McDermott(5), Bertrand Tombal(5), S. Supiot(5)